Asymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis

Diana Buitrago-Garcia (0000-0001-9761-206X),[1] Dianne Egli-Gany (0000-0002-4725-0475),[1]

Michel J Counotte (0000-0003-1039-6873),[1] Stefanie Hossmann (0000-0003-1600-5925),[2] Hira Imeri

(0000-0002-0412-1649),[1] Mert Aziz Ipekci (0000-0002-0260-9691),[1] Georgia Salanti (0000-0002-

3830-8508),[1] Nicola Low (0000-0003-4817-8986).

1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

2. Clinical Trials Unit, University of Bern, Bern, Switzerland

Corresponding author: Nicola Low nicola.low@ispm.unibe.ch

Changes from version 2

- Search updated 10.06.2020, total number of included studies increased from 37 to 94

- Protocol updated at https://osf.io/9ewys/

- New analyses
  - Review question 1, prediction intervals added for each study setting
  - Meta-analysis of secondary attack rate from asymptomatic and pre-symptomatic index cases compared with symptomatic
  - Sensitivity analysis for review question 1, omitting preprints
- Conclusions unchanged

ABSTRACT

BACKGROUND

There is disagreement about the level of asymptomatic severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) infection. We conducted a living systematic review and meta-analysis to

address three questions: 1. amongst people who become infected with SARS-CoV-2, what

proportion does not experience symptoms at all during their infection? 2. Amongst people with

SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop

symptoms later? 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are

either asymptomatic throughout infection, or pre-symptomatic?

METHODS AND FINDINGS

We searched PubMed, Embase, bioRxiv and medRxiv using a database of SARS-CoV-2 literature that

is updated daily, on 25 March 2020, 20 April 2020 and 10 June 2020. Studies of people with SARS-

CoV-2 diagnosed by reverse transcriptase PCR that documented follow-up and symptom status at

the beginning and end of follow-up, or modelling studies were included. One reviewer extracted

data and a second verified the extraction, with disagreement resolved by discussion or a third

reviewer. Risk of bias in empirical studies was assessed with an adapted checklist for case series and

the relevance and credibility of modelling studies were assessed using a published checklist. We

included a total of 94 studies. The overall estimate of the proportion of people who become infected

with SARS-CoV-2 and remain asymptomatic throughout infection was 20% (95% CI 17-25) with a

prediction interval of 3-67% in 79 studies that addressed this review question. There was some

evidence that biases in the selection of participants influence the estimate. In seven studies of

defined populations screened for SARS-CoV-2 and then followed, 31% (95% CI 26-37%, prediction

interval 24-38%) remained asymptomatic. The proportion of people that is pre-symptomatic could

not be summarised, owing to heterogeneity. The secondary attack rate was slightly lower in contacts

of people with asymptomatic infection than those with symptomatic infection (relative risk 0.35,

95% CI 0.10-1.27). Modelling studies fit to data found a higher proportion of all SARS-CoV-2

infections resulting from transmission from pre-symptomatic individuals than from asymptomatic

individuals. Limitations of the review include that most included studies were not designed to

estimate the proportion of asymptomatic SARS-CoV-2 infections and were at risk of selection biases,

we did not consider the possible impact of false negative RT-PCR results, which would underestimate

the proportion of asymptomatic infections, and that the database does not include all sources.

CONCLUSIONS

The findings of this living systematic review of publications early in the pandemic suggest that most

SARS-CoV-2 infections are not asymptomatic throughout the course of infection. The contribution of

pre-symptomatic and asymptomatic infections to overall SARS-CoV-2 transmission means that

combination prevention measures, with enhanced hand hygiene, masks, testing tracing and isolation

strategies and social distancing, will continue to be needed.

AUTHOR SUMMARY

Why was this study done?

- The proportion of people who will remain asymptomatic throughout the course of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (covid-19), is not known.

- Studies that assess people at just one time point will overestimate the proportion of true asymptomatic infection because those who go on to develop covid-19 symptoms will be wrongly classified as asymptomatic, rather than pre-symptomatic.

- The amount, and infectiousness, of asymptomatic SARS-CoV-2 infection will determine what kind of measures will prevent transmission most effectively.

What did the researchers do and find?

- We did a living systematic review through 10 June 2020, using automated workflows that speed up the review processes, and allow the review to be updated when relevant new evidence becomes available.

- Overall, in 79 studies in a range of different settings, 20% (95% confidence interval, CI 17–25%) of people with SARS-CoV-2 infection remained asymptomatic during follow-up, but biases in study designs limit the certainty of this estimate.

- We found some evidence that SARS-CoV-2 infection in contacts of people with asymptomatic infection is less likely than in contacts of people with symptomatic infection (relative risk 0.35, 95% CI 0.10-1.27).

What do these findings mean?

- The findings of this living systematic review suggest that most SARS-CoV-2 infections are not asymptomatic throughout the course of infection.

- Future studies should be designed specifically to determine the true proportion of asymptomatic SARS-CoV-2 infections, using methods to minimise biases in the selection of study participants and ascertainment of symptom status during follow up.

- The contribution of pre-symptomatic and asymptomatic infections to overall SARS-CoV-2 transmission means that combination prevention measures, with enhanced hand hygiene, masks, testing tracing and isolation strategies and social distancing, will continue to be needed.

Introduction

There is ongoing discussion about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The authors of a narrative review report a range of proportions of participants positive for SARS-CoV-2 but asymptomatic in different studies from 6 to 96% [1]. The discrepancy results, in part, from the interpretation of studies that report a proportion of asymptomatic people with SARS-CoV-2 detected at a single point. The studies cited include both people who will remain asymptomatic throughout and those, known as pre-symptomatic, who will develop symptoms of coronavirus disease 2019 (covid-19) if followed up [2]. The full spectrum and distribution of covid-19, from completely asymptomatic, to mild and non-specific symptoms, viral pneumonia, respiratory distress syndrome, and death are not yet known [3]. Without follow up, however, the proportions of asymptomatic and pre-symptomatic infections cannot be determined.

Accurate estimates of the proportions of true asymptomatic and pre-symptomatic infections are needed urgently because their contribution to overall SARS-CoV-2 transmission at the population level will determine the appropriate balance of control measures [3]. If the predominant route of transmission is from people who have symptoms, then strategies should focus on testing, followed by isolation of infected individuals and quarantine of their contacts. If, however, most transmission is from people without symptoms, social distancing measures that reduce contact with people who might be infectious, should be prioritised, enhanced by active case-finding through testing of asymptomatic people.

The objectives of this study were to address three questions: 1. Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? 2. Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or pre-symptomatic?

Methods

We conducted a living systematic review, a systematic review that provides an online summary of findings and is updated when relevant new evidence becomes available [4]. The review follows a published protocol (https://osf.io/9ewys/), which describes in detail the methods used to speed up review tasks [5] and to assess relevant evidence rapidly during a public health emergency [6]. The first two versions of the review have been published as preprints [7,8]. We report our findings according to the statement on preferred reporting items for systematic reviews and meta-analyses (S1 PRISMA Checklist) [9]. Box 1 shows our definitions of symptoms, asymptomatic infection and pre-symptomatic status. We use the term asymptomatic SARS-CoV-2 infection for people without symptoms of covid-19 who remain asymptomatic throughout the course of infection. We use the term pre-symptomatic for people who do not have symptoms of covid-19 when enrolled in a study, but who develop symptoms during adequate follow-up.

Box 1. Definitions of symptoms and symptom status in a person with SARS-CoV-2 infections

Symptoms: symptoms that a person experiences and reports. We used the authors' definitions. We searched included manuscripts for an explicit statement that the study participant did not report symptoms that they experienced. Some authors defined 'asymptomatic' as an absence of self-reported symptoms. We did not include clinical signs observed or elicited on examination.

Asymptomatic infection: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment and had no symptoms at the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

Pre-symptomatic: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment, but who developed symptoms by the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

Information sources and search

We conducted the first search on March 25, 2020 and updated it on April 20 and June 10, 2020. We

searched the covid-19 living evidence database [10], which is generated using automated workflow

processes [5] to: i) provide daily updates of searches of four electronic databases: Medline Pubmed,

Ovid Embase, bioRxiv and medRxiv, using medical subject headings and free text keywords for SARS-

CoV-2 infection and covid-19; ii) de-duplicate the records; iii) tag records that are preprints; and iv)

allow searches of titles and abstracts using Boolean operators. We used the search function to

identify studies of asymptomatic or pre-symptomatic SARS-CoV-2 infection using a search string of

medical subject headings and free text keywords (supporting information, S1 Text). We also

examined articles suggested by experts and the reference lists of retrieved mathematical modelling

studies and systematic reviews. Reports from this living rapid systematic review will be updated at

three-monthly intervals, with continuously updated searches.

Eligibility criteria

We included studies in any language of people with SARS-CoV-2 diagnosed by reverse transcriptase

PCR (RT-PCR) that documented follow-up and symptom status at the beginning and end of follow-

up, or investigated the contribution to SARS-CoV-2 transmission of asymptomatic or pre-

symptomatic infection. We included contact tracing investigations, case series, cohort studies, case-

control studies and statistical and mathematical modelling studies. We excluded the following study

types: case reports of a single patient and case series where participants were not enrolled

consecutively. Where multiple records included data from the same study population, we linked the

records and extracted data from the most complete report.

Study selection and data extraction

Reviewers worked in pairs to screen records using an application programming interface in the

electronic data capture system (REDCap, Vanderbilt University, USA). One reviewer selected

potentially eligible studies and a second reviewer verified all included and excluded studies. We

reported the identification, exclusion and inclusion of studies in a flowchart (S1 Figure). The

reviewers determined which of the three review questions each study addressed, using the

definitions in Box 1. One reviewer extracted data using a pre-piloted extraction form in REDCap and

a second reviewer verified the extracted data using the query system. A third reviewer adjudicated

on disagreements that could not be resolved by discussion. We contacted study authors for

clarification where the study description was insufficient to reach a decision on inclusion or if

reported data in the manuscript were internally inconsistent. The extracted variables included, but

were not limited to, study design, country and/or region, study setting, population, age, primary

outcomes and length of follow-up. From empirical studies, we extracted raw numbers of individuals

with any outcome and its relevant denominator. From statistical and mathematical modelling

studies we extracted proportions and uncertainty intervals reported by the authors.

The primary outcomes for each review question were: 1. Proportion with asymptomatic SARS-CoV-2

infection who did not experience symptoms at all during follow-up; 2. Proportion with SARS-CoV-2

infections who did not have symptoms at the time of testing but developed symptoms during follow-

up. 3. Estimated proportion (with uncertainty interval) of SARS-CoV-2 transmission accounted for by

people who are asymptomatic or pre-symptomatic. A secondary outcome for review question 3 was

the secondary attack rate from asymptomatic or pre-symptomatic index cases.

Risk of bias in included studies
Two authors independently assessed the risk of bias. A third reviewer resolved disagreements. For

observational epidemiological studies, we adapted the Joanna Briggs Institute Critical Appraisal

Checklist for Case Series [11]. The adapted tool included items about inclusion criteria, measurement

of asymptomatic status, follow-up of course of disease, and statistical analysis. We added items

about selection biases affecting the study population from a tool for the assessment of risk of bias in

prevalence studies [12]. For mathematical modelling studies, we used a checklist for assessing

relevance and credibility [13].

Synthesis of the evidence

We used the *metaprop* and *metabin* functions from the *meta* package (version 4.11-0) [14] in R

(version 3.5.1) to display the study findings in forest plots and synthesise their findings. The 95%

confidence intervals (CI) for each study are estimated using the Clopper-Pearson method [15]. We

examined heterogeneity visually in forest plots. We stratified studies according to the methods used

to identify people with asymptomatic SARS-CoV-2 infection and the study setting. To synthesise

proportions from comparable studies, in terms of design and population, we used stratified random

effects meta-analysis. For the stratified and overall summary estimates we calculated prediction

intervals, to represent the likely range of proportions that would be obtained in subsequent studies

conducted in similar settings [16]. We calculated the secondary attack rate as the number of cases

among contacts as a proportion of all close contacts ascertained. We did not account for potential

clustering of contacts because the included studies did not report the size of clusters. We compared

the secondary attack rate from asymptomatic or pre-symptomatic index cases with that from

symptomatic cases. If there were no events in a group, we added 0.5 to each cell in the 2x2 table.

We used random effects meta-analysis with the Mantel-Haenszel method to estimate a summary

risk ratio (with 95% CI).

Results

The living evidence database contained a total of 25538 records about SARS-CoV-2 or COVID-19 by

10 June, 2020. The searches for studies about asymptomatic or pre-symptomatic SARS-CoV-2, on 25

March, 20 April and 10 June, resulted in 89, 230 and 688 records for screening (S1 Figure). In the first

version of the review [7], 11 articles were eligible for inclusion [17-27], version 2 [8] identified

another 26 eligible records [28-53], and version 3 identified another 61 eligible records [54-114].

After excluding four articles for which more recent data became available in a subsequent version

[25,29,30,35], the total number of articles included was 94 (S1 Table) [17-24,26-28,31-34,36-114].

The types of evidence changed across the three versions of the review (S1 Table). In the first version,

six of 11 studies were contact investigations of single family clusters with a total of 39 people. In the

next versions, study designs included larger investigations of contacts and outbreaks, screening of

defined groups and studies of hospitalised adults and children. Across all three review versions, data

from 79 empirical observational studies were collected in 19 countries or territories (Tables 1 and 2)

and included 6832 people with SARS-CoV-2 infection. Forty seven of the studies, including 3802

infected people were done in China (S2 Table). At the time of their inclusion in the review, 23 of the

included records were preprints; six of these had been published in peer-reviewed journals by 17

July 2020 [19,20,27,81,82,106].

Proportion of people with asymptomatic SARS-CoV-2 infection
We included 79 studies that reported empirical data about 6616 people with SARS-CoV-2 infection

(1287 defined as having asymptomatic infection) [17,18,21-23,26-28,31,32,34,36,39-45,47-50,52-

54,56-62,64,66-68,70-77,79-90,92-112,114] and one statistical modelling study [24] (Table 1). The

sex distribution of the people with asymptomatic infection was reported in 41/79 studies and the

median age was reported in 35/79 studies (Table 1). The results of the studies were heterogeneous

(S2 Figure). We defined seven strata, according to the method of selection of asymptomatic status

and study settings. Study findings within some of these strata were more consistent (Figure 1). We

considered the statistical modelling study of passengers on the Diamond Princess cruise ship

passengers [24] separately, because of the different method of analysis and overlap with the study

population reported by Tabata S, et al. [27].

The main risks of bias across all categories of empirical studies were in the selection and enrolment

of people with asymptomatic infection and mismeasurement of asymptomatic status because of

absent or incomplete definitions (S3 Figure). Sources of bias specific to studies in particular settings

are discussed with the relevant results.

The overall estimate of the proportion of people who become infected with SARS-CoV-2 and remain

asymptomatic throughout the course of infection was 20% (95% CI 17–25%, 79 studies), with a

prediction interval of 3 to 67% (Figure 1). One statistical modelling study was based on data from all

634 passengers from the Diamond Princess Cruise ship with RT-PCR positive test results [24]. The

authors adjusted for the proportion of people who would develop symptoms (right censoring) in a

Bayesian framework to estimate that, if all were followed up until the end of the incubation period,

the probability of asymptomatic infections would be 17.9% (95% credibility interval, CrI 15.5–20.2%).

Table 1. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections

Author	Country, location	Total SARS-CoV-2, n	Asymptomatic SARS-CoV-2, n	Sex of asymptomatic people	Age of asymptomatics, years, median	Follow-up method[a]
Contact investigation, single						
Tong, ZD [44]	China, Zhejiang	5	3	2F, 3M	28 IQR 12-41	1, 3
Huang, R [74]	China, Suquian	2	1	1F, 0M	54	3
Jiang, XL [76]	China, Shandong	8	3	3F, 0M	35 IQR 0-53	3
Jiang, X [75]	China, Chongqing	3	1	1F, 0M	8	2
Liao, J [22]	China, Chongqing	12	3	NR	NR	1,2
Hu, Z [21]	China, Nanjing	4	1	0F, 1M	64	2, 3
Luo, SH [23]	China, Anhui	4	1	1F, 0M	50	1,2,3
Chan, JF [18]	China, Guangdong	5	1	0F ,1M	10	1
Ye, F [49]	China, Sichuan	5	1	0F, 1M	28	1,2
Bai, Y [17]	China, Anyang	6	1	1F, 0M	20	1
Luo, Y [85]	China, Wuhan	6	5	NR	37 IQR 7-62	1
Zhang, J [50]	China, Wuhan & Beijing	5	2	1F, 1M	NR	2
Zhang, B [110]	China, Guangdong	7	2	0F, 2M	13.5 IQR 13-14	3
Huang, L [73]	China, Gansu	7	2	2F, 0M	44 IQR 38.5-49.5	2
Qian, G [26]	China, Zhejiang	8	2	1F, 1M	30.5 IQR 1, 60	1,2
Gao, Y [70]	China, Wuxi	15	6	3F, 3M	50 IQR 48-51	1,2
Contact investigation, aggregated						
Hijnen, D [72]	Germany	11	1	0F, 1M	49	1
Brandstetter, S [62]	Germany	36	2	NR	NR	2
Zhang, W2 [111]	China, Guiyang	12	4	NR	NR	1, 2, 3
Cheng, HY [66]	Taiwan	22	4	NR	NR	1
Wang, Z [47]	China, Wuhan	47	4	NR	NR	1
Wu, J [105]	China, Zhuhai	83	8	NR	NR	1,2

Luo, L [36]	China, Guangzhou	129	8	NR	NR	1, 2, 3
Bi, Q [60]	China, Shenzhen	87	17	NR	NR	2,3
Yang, R [108]	China, Wuhan	78	33	22F, 11M	37 IQR 26-45	3

Outbreak investigation

Danis, K [32]	France	13	1	NR	NR	1, 2
Böhmer, MM [61]	Germany	16	1	NR	NR	1
Roxby, AC [94]	USA	6	3	NR	NR	1
Yang, N [48]	China, Xiaoshan	10	2	1F, 1M	NR	1, 2
Schwierzeck, V [95]	Germany	12	2	NR	NR	2
Arons, MM [58]	USA	47	3	NR	NR	2
Park, SY [90]	South Korea	97	4	NR	NR	2
Dora, AV [68]	USA	19	6	0F, 6M	75 IQR 72-75	3
Tian, S [43]	China, Shandong	24	7	NR	NR	3
Solbach, W [97]	Germany	97	10	NR	NR	2
Graham, N [71]	United Kingdom	126	46	NR	NR	2
Pham, TQ [100]	Vietnam	208	89	NR	31 IQR 23-45	2

Screening of defined population

Hoehl, S [34]	Germany	2	1	0F, 1M	58	2
Chang, L [31]	China, Wuhan	4	2	0F, 2M	45 IQR 37-53	2
Arima, Y [28]	Japan	12	4	NR	NR	1, 2
Rivett, L [93]	United Kingdom	30	5	NR	NR	2
Treibel, TA [101]	United Kingdom	44	12	NR	NR	2
Lavezzo, E [81]	Italy	73	29	NR	NR	2
Lombardi, A [82]	Italy	138	41	NR	NR	3

Hospitalised adults

Pongpirul, WA [39]	Thailand	11	1	1F, 0M	66	2, 3
Zou, L [53]	China, Zhuhai	18	1	1M, 0M	26	1
Qiu, C [92]	China, Hunan	104	5	NR	NR	2
Zhou, R [114]	China, Guangdong	31	9	NR	NR	3
Chang, MC [64]	South Korea	139	10	4F, 6M	NR	1, 2
Zhou, X [52]	China, Shanghai	328	10	NR	NR	1, 2, 3
Angelo Vaira, L [57]	Italy	345	10	NR	NR	3
Wang, X [45]	China, Wuhan	1012	14	NR	NR	1, 2
Wong, J [103]	Brunei	138	16	NR	NR	2,3
Xu, T [107]	China, Jiangsu	342	15	5F, 10M	27 IQR 17-36	2, 3
London, V [83]	USA	68	22	22F, 0M	30.5	2

					IQR 24.5-34.8	
Tabata, S [27]	Japan[b]	104	33	18F, 15M	70 IQR 57-75	2
Andrikopoulou, M [56]	USA	158	46	46F, 0M	NR	1, 2
Noh, JY [89]	South Korea	199	53	NR	NR	3
Kumar, R [80]	India, New Delhi	231	108	18F, 90M	NR	2, 3
Hospitalised children						
See, KC [41]	Malaysia	4	1	0F, 1M	9	1, 2, 3
Tan, YP [42]	China, Changsha	10	2	1F, 1M	8	2, 3
Tan, X [99]	China, Changsha	13	2	2F, 0M	5 IQR 2-8	1,2, 3
Melgosa, M [87]	Spain	16	3	NR	NR	1,2
Wu, HP [104]	China, Jiangxi	23	3	NR	NR	3
Song, W [98]	China, Hubei	16	8	3F, 5M	11 IQR 7-12	1, 2
Bai, K [59]	China, Chongqing	25	8	NR	NR	3
Xu, H [106]	China, Guizhou	32	11	4F, 7M	NR	1, 2
Qiu, H [40]	China, Zhejiang	36	10	NR	NR	1, 2, 3
Lu, Y [84]	China, Wuhan	110	29	12 F, 17M	7 IQR 6-11	2, 3
Hospitalised adults and children						
Merza, MA [88]	Iraqi Kurdistan	15	6	NR	NR	2, 3
Yongchen, Z [109]	China, Jiangsu	21	5	2F, 3M	25 IQR 14-54	1, 2, 3
Ma, Y [86]	China, Shandong	47	11	5F, 6M	23 IQR NR	2
Kim, SE [77]	South Korea	71	10	6F, 4M	31 IQR 21-55	2
Choe, PG [67]	South Korea	113	15	17F, 8 M	NR	3
Sharma, AK [96]	India, Jaipur	234	215	NR	NR	1, 2, 3
Zhang, W3 [112]	China, Guiyang	137	26	12F, 14M	24 IQR 12-36	1, 2
Alshami, AA [54]	Saudi Arabia	128	69	36, 33M	NR	2,3
Kong, W [79]	China, Sichuan	473	45	NR	NR	1, 2
Wang, Y2 [102]	China, Chongqing	279	63	29F, 34M	39 IQR 27-53	3

232
233 Abbreviations: F, female; IQR, interquartile range; M, male; NR, not reported; USA, United States of America
234 a. Follow-up according to protocol (1, 14 days after last possible exposure; 2, seven days after diagnosis; 3, until
235   negative RT-PCR result);
236 b. People of different nationalities taken from Diamond Princess cruise ship to a hospital in Japan.
237

Figure 1. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by setting.
The x-axis displays proportions. In the setting 'Contact investigations' where more than one cluster was
reported, clusters are annotated with '[cluster]'. The diamond shows the summary estimate and its 95%
confidence interval. The red bar and red text show the prediction interval.

The summary estimates of the proportion of people with asymptomatic SARS-CoV-2 infection

differed according to study setting, although prediction intervals for all groups overlapped. The first

three strata in Figure 1 involve studies that reported on different types of contact investigation,

which start with an identified covid-19 case. The studies reporting on single family clusters (21

estimates from 16 studies in China, n=102 people with SARS-CoV-2) all included at least one

asymptomatic person [17,18,21-23,26,44,49,50,70,73-76,85,110]. The summary estimate was 34%

(95% CI 26–44%, prediction interval 25–45%). In nine studies that reported on close contacts of

infected individuals and aggregated data from clusters of both asymptomatic and symptomatic

people with SARS-CoV-2 the summary estimate was 14% (95% CI 8–23%, prediction interval 2–53%)

[36,47,60,62,66,72,105,108,111]. We included 12 studies (n=675 people) that reported on outbreak

investigations arising from a single symptomatic person, or from the country's first imported cases of

people with covid-19 [32,43,48,58,61,68,71,90,94,95,97,100]. Four of the outbreaks involved nursing

homes [58,68,71,94] and four involved occupational settings [43,61,90,95]. The summary estimate

of the proportion of asymptomatic SARS-CoV-2 infections was 18% (95% CI 10–28%, prediction

interval 10–28%).

In seven studies, people with SARS-CoV-2 infection were detected through screening of all people in

defined populations who were potentially exposed (303 infected people amongst 10090 screened)

[28,31,34,81,82,93,101]. The screened populations included healthcare workers [82,93,101], people

evacuated from a setting where SARS-CoV-2 transmission was confirmed, irrespective of symptom

status [28,34], the whole population of one village in Italy [81] and blood donors [31]. In these

studies, the summary estimate of the proportion asymptomatic was 31% (95% CI 26–37%, prediction

interval 24–38%). There is a risk of selection bias in studies of certain groups, such as healthcare

workers and blood donors, because people with symptoms are excluded [31,82,93,101] or from non-

responders in population-based screening [81]. Retrospective symptom ascertainment could also

increase the proportion determined asymptomatic [81,82,101].

The remaining studies, in hospital settings, included adult patients only (15 studies, n=3228)

[27,39,45,52,53,56,57,64,80,83,89,92,103,107,114], children only (10 studies, n=285) [40-

42,59,84,87,98,99,104,106] or adults and children (10 studies, n=1518)

[54,67,77,79,86,88,96,102,109,112] (Table 1, Figure 1). The types of hospital and clinical severity of

patients differed, including settings in which anyone with SARS-CoV-2 infection was admitted for

isolation and traditional hospitals.

Proportion of pre-symptomatic SARS-CoV-2 infections

We included 31 studies in which the people with no symptoms of covid-19 at enrolment were

followed up and the proportion that develops symptoms is defined as pre-symptomatic (Table 2,

Figure 2)

[21,27,28,31,34,37,38,41,45,46,49,52,55,56,58,67,68,71,73,76,77,79,81,90,93,95,103,110,111,113,1

14]. Four studies addressed only this review question [37,38,55,113]. The findings from the 31

studies were heterogeneous (S4 Figure), even when categorised according to the method of

selection of asymptomatic participants, and we did not estimate a summary measure (Figure 2).

Table 2. Characteristics of studies that measured the proportion of people with SARS-CoV-2 infection that develops symptoms

Author	Country, location	Total asymptomatic SARS-CoV-2, n	Develops symptoms after testing, n	Sex, asymptomatics at time of testing	Age of asymptomatics at time of testing, years, median	Follow-up method[a]
Contact investigation, single						
Ye, F [49]	China, Sichuan	3	2	0F, 3M	28 IQR 23-50	1, 2
Zhang, B [110]	China, Guangdong	4	2	0F, 4M	34 IQR 33-35	3
Huang, L [73]	China, Gansu	4	2	3F, 1M	44.5 IQR 34.50-54.25	2
Jiang, XL [76]	China, Shandong	5	2	3F, 2M	35 IQR 35-37	3
Hu, Z [21]	China, Nanjing	24	5	NR	NR	2, 3
Contact investigation, aggregated						
Zhang, W2 [111]	China, Guangzhou	12	8	NR	NR	1,2,3
Outbreak investigation						
Schwierzeck, V [95]	Germany	6	4	NR	NR	2
Park, SY [90]	South Korea	8	4	NR	NR	2
Arons, MM [58]	USA	27	24	NR	NR	2
Dora, AV [68]	USA	14	8	0F, 14M	NR	3
Graham, N [71]	United Kingdom	54	8	NR	NR	1
Screening of defined population						
Hoehl, S [34]	Germany	2	1	1F, 1M	51	2
Rivett, L [93]	United Kingdom	6	1	NR	NR	2
Chang, L [31]	China, Wuhan	4	2	1F, 3M	39.5 IQR 29-47.5	2
Arima, Y [28]	Japan	5	2	NR	NR	1, 2
Lytras, T [37]	Greece	39	4	NR	NR	2

Study	Location			Sex	Age	Follow-up[a]
Lavezzo, E [81]	Italy	39	10	NR	NR	2
Hospitalised adults						
Al-Shamsi, HO [55]	United Arab Emirates	7	7	5F, 2M	51.6 IQR 40-76	3
Luo, SH [23]	China, Anhui	8	7	NR	NR	1, 2, 3
Zhou, X [52]	China, Shanghai	13	3	7F, 6M	NR	2, 3
Zhou, R [114]	China, Guangdong	31	22	NR	NR	3
Wang, X [45]	China, Wuhan	30	16	NR	NR	1, 2
Tabata, S [27]	Cruise Ship	43	10	24F, 19M	69 IQR 60.5-75	2
Wang, Y1 [46]	China, Shenzhen	55	43	NR	49 IQR 2-69	3
Meng, H [38]	China, Wuhan	58	16	NR	NR	2
Andrikopoulou, M [56]	USA	63	16	63F, 0M	NR	1, 2
Zhang, Z [113]	China, Shenzhen	56	33	33F, 23M	NR	2,3
Wong, J [103]	Brunei	138	42	NR	NR	2, 3
Hospitalised children						
See, KC [41]	Malaysia	2	1	0F, 2M	5 IQR 1-9	1, 2, 3
Hospitalised adults and children						
Kim, SE [77]	South Korea	13	3	7F, 6M	31 IQR 20.5-51.5	2
Choe, PG [67]	South Korea	54	39	32F, 22M	NR	3
Kong, W [79]	China, Sichuan	62	17	NR	NR	1

Abbreviations: F, female; IQR, interquartile range; M, male; NR, not reported; USA, United States of America

a. Follow-up according to protocol (1, 14 days after possible exposure; 2, seven days after diagnosis; 3, until one or more negative RT-PCR result);

b. People of different nationalities taken from Diamond Princess cruise ship to a hospital in Japan

c. Until hospital discharge or negative RT-PCR.

Study	Events	Total		Prop.	95% CI
Contact investigation					
Ye, F	2	3		0.67	[0.09;0.99]
Zhang, B	2	4		0.50	[0.07;0.93]
Huang, L	2	4		0.50	[0.07;0.93]
Jiang, XL	2	5		0.40	[0.05;0.85]
Hu, Z	5	24		0.21	[0.07;0.42]
Contact investigation, aggregated					
Zhang, W2	8	12		0.67	[0.35;0.90]
Outbreak investigation					
Schwierzeck, V	4	6		0.67	[0.22;0.96]
Park, SY	4	8		0.50	[0.16;0.84]
Arons, MM	24	27		0.89	[0.71;0.98]
Dora, AV	8	14		0.57	[0.29;0.82]
Graham, N	8	54		0.15	[0.07;0.27]
Screening					
Hoehl, S	1	2		0.50	[0.01;0.99]
Rivett, L	1	6		0.17	[0.00;0.64]
Chang, L	2	4		0.50	[0.07;0.93]
Arima, Y	2	5		0.40	[0.05;0.85]
Lytras, T	4	39		0.10	[0.03;0.24]
Lavezzo, E	10	39		0.26	[0.13;0.42]
Hospitalised adults					
Al−Shamsi, HO	7	7		1.00	[0.59;1.00]
Zhou, X	3	13		0.23	[0.05;0.54]
Zhou, R	22	31		0.71	[0.52;0.86]
Wang, X	16	30		0.53	[0.34;0.72]
Tabata, S	10	43		0.23	[0.12;0.39]
Wang, Y1	43	55		0.78	[0.65;0.88]
Meng, H	16	58		0.28	[0.17;0.41]
Andrikopoulou, M	16	63		0.25	[0.15;0.38]
Zhang, Z	33	56		0.59	[0.45;0.72]
Wong, J	42	138		0.30	[0.23;0.39]
Hospitalised children					
See, KC	1	2		0.50	[0.01;0.99]
Hospitalised adults & children					
Kim, SE	3	13		0.23	[0.05;0.54]
Choe, PG	39	54		0.72	[0.58;0.84]
Kong, W	17	62		0.27	[0.17;0.40]

0   0.25   0.5   0.75   1

Figure 2. Forest plot of proportion of people with pre-symptomatic SARS-CoV-2 infection, stratified by setting. The x-axis displays proportions.

Additional analyses

We investigated heterogeneity in the estimates of the proportion of asymptomatic SARS-CoV-2

infections in subgroup analyses that were not specified in the original protocol. In studies of

hospitalised children, the point estimate was higher (25%, 95% CI 14–40%, 10 studies) than in adults

(11%, 95% CI 7–17%, 15 studies), but confidence intervals overlapped (Figure 1). The proportion of

asymptomatic SARS-CoV-2 infection estimated in studies of hospitalised patients (35 studies, 19%,

95% CI 14–25%) was similar to that in all other settings (44 studies, 22%, 95% CI 17–29%, S5 Figure).

To examine publication status, we conducted a sensitivity analysis, omitting studies that were

identified as preprints at the time of data extraction (S6 Figure). The estimate of the proportion of

asymptomatic infection in all settings (18%, 95% CI 14–22%) and setting-specific estimates were very

similar to the main analysis.

Contribution of asymptomatic and pre-symptomatic infection to SARS-CoV-2 to transmission

Five of the studies that conducted detailed contact investigations provided enough data to calculate

a secondary attack rate according to the symptom status of the index cases (Figure 3)

[36,65,66,90,111]. The summary risk ratio for asymptomatic compared with symptomatic was 0.35

(95% CI 0.1–1.27) and for pre-symptomatic compared with symptomatic people was 0.63 (95% CI

0.18–2.26) [66,90]. The risk of bias in ascertainment of contacts was judged to be low in all studies.

Figure 3. Forest plot of the risk ratio (RR) and 95% confidence interval (CI) of the secondary attack rate (SAR),
comparing infections in contacts of asymptomatic and pre-symptomatic index cases with infections in contacts
of symptomatic cases. E, number of secondary transmission events; N, number of close contacts. The x-axis
shows the risk ratio on a logarithmic scale.
322

We included eight mathematical modelling studies (Figure 4) [19,20,33,51,63,69,78,91]. The models

in five studies were informed by analysis of data from contact investigations in China, South Korea,

Singapore, and the Diamond Princess cruise ship, using data to estimate the serial interval or

generation time [19,20,33,69,78] and in three studies the authors used previously published

estimates [51,63,91].

Estimates of the contributions of both asymptomatic and pre-symptomatic infections SARS-CoV-2

transmission were very heterogeneous. In two studies, the contribution to SARS-CoV-2 transmission

of asymptomatic infection were estimated to be 6% (95% CrI 0–57%) [19] and 69% (95% CrI 20–85%)

[69] (Figure 4). The estimates have large uncertainty intervals and the disparate predictions result

from differences in the proportion of asymptomatic infections and relative infectiousness of

asymptomatic infection. Ferretti L, et al. provide an interactive web application [ref:link], which

shows how these parameters affect the model results.

Models of the contribution of pre-symptomatic transmission used different assumptions about the

durations and distributions of infection parameters such as incubation period, generation time and

serial interval [19,20,33,51,63,78,91]. In models that accounted for uncertainty appropriately, most

estimates of the proportion of transmission resulting from people with SARS-CoV-2 who are pre-

symptomatic ranged from 20 to 70%. In one study that estimated a contribution of <1% [91], the

model fitted serial interval was longer than observed in empirical studies [115]. The credibility of

most modelling studies was limited by the absence of external validation. The data to which the

models were fitted were generally from small samples (S7 Figure).

Figure 4. Forest plot of proportion of SARS-CoV-2 infection resulting from asymptomatic or pre-symptomatic
transmission. For studies that report outcomes in multiple settings, these are annotated in brackets. SI, serial
interval; GI: generation interval.
347

Discussion

Summary of main findings

The summary proportion of SARS-CoV-2 that is asymptomatic throughout the course of infection was estimated to be 20% (95% CI 17–25%, 79 studies), with a prediction interval of 3–67%. In studies that identified SARS-CoV-2 infection through screening of defined populations, the proportion of asymptomatic infections was 31% (95% CI 26–37%, 7 studies). In 31 studies reporting on people who are pre-symptomatic but who go on to develop symptoms, the results were too heterogeneous to combine. The secondary attack rate from asymptomatic infections may be lower than that from symptomatic infections (relative risk 0.35, 95% CI 0.1–1.27). Modelling studies estimated a wide range of the proportion of all SARS-CoV-2 infections that result from transmission from asymptomatic and pre-symptomatic individuals.

Strengths and weaknesses

A strength of this review is that we used clear definitions and separated review questions to distinguish between SARS-CoV-2 infections that remain asymptomatic throughout their course from those that become symptomatic, and to separate proportions of people with infection from their contribution to transmission in a population. This living systematic review uses methods to minimise bias whilst increasing the speed of the review process [5,6], and will be updated regularly. We only included studies that provided information about follow-up through the course of infection, which allowed reliable assessment about the proportion of asymptomatic people in different settings. In the statistical synthesis of proportions, we used a method that accounts for the binary nature of the data and avoids the normality approximation (weighted logistic regression).

Limitation of the review are that most included studies were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infection and definitions of asymptomatic status were often incomplete or absent. The risks of bias, particularly those affecting selection of participants, differed between studies and could result in both underestimation and overestimation of the true proportion of asymptomatic infections. Also, we did not consider the possible impact of false negative RT-PCR results, which might be more likely to occur in asymptomatic infections [116] and

would underestimate the proportion of asymptomatic infections [117]. The four databases that we

searched are not comprehensive, but they cover the majority of publications and we do not believe

that we have missed studies that would change our conclusions.

Comparison with other reviews

We found narrative reviews that reported wide ranges (five to 96%) of infections that might be

asymptomatic [1,118]. These reviews presented cross-sectional studies alongside longitudinal

studies and did not distinguish between asymptomatic and pre-symptomatic infection. We found

three systematic reviews, which reported similar summary estimates from meta-analysis of studies

published up to May [119-121]. In two reviews, authors applied inclusion criteria to reduce the risks

of selection bias, with summary estimates of 11% (95% CI 4–18%, 6 studies) [120] and 15% (95% CI

12–18%, 9 studies) [121]. Our review includes all these studies, mostly in the categories of

aggregated contact or outbreak investigations, with compatible summary estimates (Figure 1). We

categorised one report [81] with other studies in which a defined population was screened. The

summary estimate in the third systematic review (16%, 95% CI 10–23%, 41 studies) [119] was

similar to that of other systematic reviews, despite inclusion of studies with no information about

follow-up. In comparison with other reviews, rather than restricting inclusion, we give a

comprehensive overview of studies with adequate follow-up, with assessment of risks of bias and

exploration of heterogeneity (S2-S7 Figures). The three versions of this review to date have shown

how types of evidence change over time, from single family investigations to large screening studies

(S1 Table).

Interpretation

The findings from systematic reviews, including ours [119-121], do not support the claim that a large

majority of SARS-CoV-2 infections are asymptomatic [122]. We estimated that, across all study

settings, the proportion of SARS-CoV-2 infections that is asymptomatic throughout the course of

infection is 20% (95% CI 17–25%). The wider prediction interval reflects the heterogeneity between

studies and indicates that future studies with similar study designs and in similar settings will

estimate a proportion of asymptomatic infections from three to 67%. Studies that detect SARS-CoV-

2 through screening of defined populations irrespective of infection status at enrolment should be

less affected by selection biases. In this group of studies, the estimated proportion of asymptomatic

infection was 31% (95% CI 26–37%, prediction interval 24–38%). This estimate suggests that other

studies might have had an over-representation of participants diagnosed because of symptoms, but

there were also potential selection biases in screening studies that might have overestimated the

proportion of asymptomatic infections. Our knowledge to date is based on data collected during the

acute phase of an international public health emergency, mostly for other purposes. To estimate the

true proportion of asymptomatic SARS-CoV-2 infections, researchers need to design prospective

longitudinal studies with clear definitions, methods that minimise selection and measurement

biases, and transparent reporting. Serological tests, in combination with virological diagnostic

methods, might improve ascertainment of SARS-CoV-2 infection in asymptomatic populations.

Prospective documentation of symptom status would be required, and improvements in the

performance of serological tests are still needed [123].

Our review adds to information about the relative contributions of asymptomatic and pre-

symptomatic infection to overall SARS-CoV-2 transmission. Since all people infected with SARS-CoV-2

are initially asymptomatic, the proportion that will go on to develop symptoms can be derived by

subtraction from the estimated proportion with true asymptomatic infections; from our review, we

would estimate this fraction to be 80% (95% CI 75–83%). Since SARS-CoV-2 can be transmitted a few

days before the onset of symptoms [124], pre-symptomatic transmission likely contributes

substantially to overall SARS-CoV-2 epidemics. The analysis of secondary attack rates provides some

evidence of lower infectiousness of people with asymptomatic than symptomatic infection (Figure 3)

[36,65,66,90,111], but more studies are needed to quantify this association more precisely. If both

the proportion and transmissibility of asymptomatic infection are relatively low, people with

asymptomatic SARS-CoV-2 infection should account for a smaller proportion of overall transmission

than pre-symptomatic individuals. This is consistent with the findings of the only mathematical

modelling study in our review that explored this question [19]. Uncertainties in estimates of the true

proportion and the relative infectiousness of asymptomatic SARS-Cov-2 infection and other infection

parameters contributed to heterogeneous predictions about the proportion of pre-symptomatic

transmission [20,33,51,63,78,91].

Implications and unanswered questions

Integration of evidence from epidemiological, clinical and laboratory studies will help to clarify the

relative infectiousness of asymptomatic SARS-CoV-2. Studies using viral culture as well as RNA

detection are needed since RT-PCR defined viral loads appear to be broadly similar in asymptomatic

and symptomatic people [116,125]. Age might play a role as children appear more likely than adults

to have an asymptomatic course of infection (Figure 1) [126]; age was poorly reported in studies

included in this review (Table 1).

SARS-CoV-2 transmission from people who are either asymptomatic or pre-symptomatic has

implications for prevention. Social distancing measures will need to be sustained at some level

because droplet transmission from close contact with people with asymptomatic and pre-

symptomatic infection occurs. Easing of restrictions will, however, only be possible with wide access

to testing, contact tracing and rapid isolation of infected individuals. Quarantine of close contacts is

also essential to prevent onward transmission during asymptomatic or pre-symptomatic periods of

those that have become infected. Digital, proximity tracing could supplement classical contact

tracing to speed up detection of contacts to interrupt transmission during the pre-symptomatic

phase if shown to be effective [19,127]. The findings of this systematic review of publications early in

the pandemic suggests that most SARS-CoV-2 infections are not asymptomatic throughout the

course of infection. The contribution of pre-symptomatic and asymptomatic infections to overall

SARS-CoV-2 transmission means that combination prevention measures, with enhanced hand and

respiratory hygiene, testing tracing and isolation strategies and social distancing, will continue to be

needed.

Supporting Information

Supporting Information

S1 PRISMA Checklist

S1 Text. Search strings

S1 Figure. Flow chart

S2 Figure. Review question 1, forest plot of included studies, by study precision

S3 Figure. Risk of bias in studies included in review question 1 and review question 2

S4 Figure: Review question 2, forest plot of included studies, by study precision

S5 Figure: Sub-group analysis, review question 1, comparing studies of hospitalised patients with all
other settings

S6 Figure: Sensitivity analysis, review question 1, omitting studies that were preprints at the time of
literature search

S7 Figure. Assessment of credibility of mathematical modelling studies

S1 Table. Types of study included in successive versions of the living systematic review, as of 10 June
2020

S2. Table. Location of studies contributing data to review questions 1 and 2

References

1.   Oran DP, Topol EJ. Prevalence of Asymptomatic Sars-Cov-2 Infection: A Narrative Review.
Ann Intern Med. 2020. Epub 2020/06/04. doi: 10.7326/M20-3012. PubMed PMID: 32491919.

2.   World Health Organization. Coronavirus Disease 2019 (Covid-19) Situation Report - 73.
Geneva: 2020.

3.   Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed.
N Engl J Med. 2020. Epub 2020/02/20. doi: 10.1056/NEJMp2002125. PubMed PMID: 32074416.

4.   Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, Gruen RL. Living
Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. PLoS Med.
2014;11(2):e1001603. doi: 10.1371/journal.pmed.1001603. PubMed PMID: 24558353; PubMed
Central PMCID: PMC3928029.

5.   Thomas J, Noel-Storr A, Marshall I, Wallace B, McDonald S, Mavergames C, Glasziou P,
Shemilt I, Synnot A, Turner T, Elliott J, Living Systematic Review N. Living Systematic Reviews: 2.
Combining Human and Machine Effort. J Clin Epidemiol. 2017;91:31-7. Epub 2017/09/16. doi:
10.1016/j.jclinepi.2017.08.011. PubMed PMID: 28912003.

6.   Rapid Reviews to Strengthen Health Policy and Systems: A Practical Guide. Geneva: World
Health Organization; 2017. Available from:
https://apps.who.int/iris/bitstream/handle/10665/258698/9789241512763-eng.pdf;sequence=1.

7.   Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, Low N. The Role
of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis. Version
1. medRxiv. [Preprint]. 2020. doi: https://doi.org/10.1101/2020.04.25.20079103 PubMed PMID.

8.   Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, Low N. The Role
of Asymptomatic Sars-Cov-2 Infections: Rapid Living Systematic Review and Meta-Analysis. Version
2. medRxiv. [Preprint]. 2020. doi: https://doi.org/10.1101/2020.04.25.20079103 PubMed PMID.

9.   Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux
PJ, Kleijnen J, Moher D. The Prisma Statement for Reporting Systematic Reviews and Meta-Analyses
of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med.
2009;6(7):e1000100. doi. PubMed PMID.

10.   Counotte M, Imeri H, Ipekci M, Low N. **Covid-19 Living Evidence** Bern: Institute of Social and
Preventive Medicine, University of Bern; 2020 [Access Date; cited 2020 09.05.2020]. Covid-19 living
evidence landing page]. Available from: https://ispmbern.github.io/covid-19/living-review/.

11.   Joanna Briggs Institute. **The Joanna Briggs Institute Critical Appraisal Tools for Use in Jbi**
Systematic Reviews–Checklist for Case Series Adelaide2017 [Access Date:10.06.2020]. Available
from: https://joannabriggs.org/ebp/critical_appraisal_tools.

12.   Boyle MH. Guidelines for Evaluating Prevalence Studies. Evid Based Ment Health.
1998;1(2):37-40. doi. PubMed PMID.

13.   Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, Briggs AH, Forces I-A-NMCT.
Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care
Decision Making: An Ispor-Amcp-Npc Good Practice Task Force Report. Value Health.
2014;17(2):174-82. doi: 10.1016/j.jval.2014.01.003. PubMed PMID: 24636375.

14.   Balduzzi S, Rucker G, Schwarzer G. How to Perform a Meta-Analysis with R: A Practical
Tutorial. Evid Based Ment Health. 2019;22(4):153-60. Epub 2019/09/30. doi: 10.1136/ebmental-
2019-300117. PubMed PMID: 31563865.

15.   Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of
Seven Methods. Stat Med. 1998;17(8):857-72. doi. PubMed PMID.

16.   Riley RD, Higgins JP, Deeks JJ. Interpretation of Random Effects Meta-Analyses. BMJ.
2011;342:d549. doi. PubMed PMID.

17.   Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. Presumed Asymptomatic Carrier
Transmission of Covid-19. JAMA. 2020;54(0):E017. doi: 10.1001/jama.2020.2565. PubMed PMID.

18.   Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK,
Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A Familial Cluster of
Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: A
Study of a Family Cluster. Lancet. 2020;395(10223):514-23. Epub 2020/01/28. doi: 10.1016/S0140-
6736(20)30154-9. PubMed PMID: 31986261; PubMed Central PMCID: 7159286.

19.   Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, Parker M, Bonsall D,
Fraser C. Quantifying Sars-Cov-2 Transmission Suggests Epidemic Control with Digital Contact
Tracing. Science. 2020;368(6491):2020.03.08.20032946. Epub 2020/04/03. doi:
10.1126/science.abb6936. PubMed PMID: 32234805; PubMed Central PMCID: 7164555.

20.   Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, Hens N. Estimating the
Generation Interval for Coronavirus Disease (Covid-19) Based on Symptom Onset Data, March 2020.
Euro Surveill. 2020;25(17):2020.03.05.20031815. Epub 2020/05/07. doi: 10.2807/1560-
7917.ES.2020.25.17.2000257. PubMed PMID: 32372755; PubMed Central PMCID: 7201952.

21.   Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y, Shen
H. Clinical Characteristics of 24 Asymptomatic Infections with Covid-19 Screened among Close
Contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706-11. Epub 2020/03/09. doi:
10.1007/s11427-020-1661-4. PubMed PMID: 32146694; PubMed Central PMCID: 7088568.

22.   Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, Li C, Zhang X, Wu C, Mou H, Song C, Li F, Wu G, Zhang
J, Guo L, Liu H, Lv J, Xu L, Lang C. Epidemiological and Clinical Characteristics of Covid-19 in
Adolescents and Young Adults. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.03.10.20032136.
PubMed PMID.

23.   Luo SH, Liu W, Liu ZJ, Zheng XY, Hong CX, Liu ZR, Liu J, Weng JP. A Confirmed Asymptomatic
Carrier of 2019 Novel Coronavirus. Chin Med J (Engl). 2020;133(9):1123-5. Epub 2020/03/10. doi:
10.1097/CM9.0000000000000798. PubMed PMID: 32149768.

24.   Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the Asymptomatic Proportion of
Coronavirus Disease 2019 (Covid-19) Cases on Board the Diamond Princess Cruise Ship, Yokohama,
Japan, 2020. Euro Surveill. 2020;25(10). Epub 2020/03/19. doi: 10.2807/1560-
7917.ES.2020.25.10.2000180. PubMed PMID: 32183930; PubMed Central PMCID: 7078829.

25.   Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, Yang Y, Yuan B,
Akhmetzhanov AR, Linton NM, Miyama T. Estimation of the Asymptomatic Ratio of Novel
Coronavirus Infections (Covid-19). Int J Infect Dis. 2020. doi: 10.1016/j.ijid.2020.03.020. PubMed
PMID.

26.   Qian G, Yang N, Ma AHY, Wang L, Li G, Chen X, Chen X. A Covid-19 Transmission within a
Family Cluster by Presymptomatic Infectors in China. Clin Infect Dis. 2020. doi: ciaa316. PubMed
PMID.

27.   Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, Obinata H, Mimura S, Kodera T,
Kitagaki M, Sato M, Suzuki S, Ito T, Uwabe Y, Tamura K. Non-Severe Vs Severe Symptomatic Covid-
19: 104 Cases from the Outbreak on the Cruise Ship 'Diamond Princess' in Japan. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.03.18.20038125. PubMed PMID.

28.   Arima Y, Shimada T, Suzuki M, Suzuki T, Kobayashi Y, Tsuchihashi Y, Nakamura H,
Matsumoto K, Takeda A, Kadokura K, Sato T, Yahata Y, Nakajima N, Tobiume M, Takayama I,
Kageyama T, Saito S, Nao N, Matsui T, Sunagawa T, Hasegawa H, Ohnishi M, Wakita T. Severe Acute
Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020.
Emerg Infect Dis. 2020;26(7). Epub 2020/04/11. doi: 10.3201/eid2607.200994. PubMed PMID:
32275498.

29.   Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, Ring L, Landau
R, Purisch S, Friedman AM, Fuchs K, Sutton D, Andrikopoulou M, Rupley D, Sheen JJ, Aubey J, Zork N,
Moroz L, Mourad M, Wapner R, Simpson LL, D'Alton ME, Goffman D. Covid-19 Infection among
Asymptomatic and Symptomatic Pregnant Women: Two Weeks of Confirmed Presentations to an
Affiliated Pair of New York City Hospitals. Am J Obstet Gynecol MFM. 2020:100118. Epub
2020/04/16. doi: 10.1016/j.ajogmf.2020.100118. PubMed PMID: 32292903; PubMed Central PMCID:
PMC7144599.

30.   Le TQM, Takemura T, Moi ML, Nabeshima T, Nguyen LKH, Hoang VMP, Ung THT, Le TT,
Nguyen VS, Pham HQA, Duong TN, Nguyen HT, Ngu DN, Nguyen CK, Morita K, Hasebe F, Dang DA.
Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers, Vietnam, 2020. Emerg
Infect Dis. 2020. doi: 10.3201/eid2607.200591. PubMed PMID.

31.   Chang L, Zhao L, Gong H, Wang L, Wang L. Severe Acute Respiratory Syndrome Coronavirus 2
Rna Detected in Blood Donations. Emerg Infect Dis. 2020;26(7). Epub 2020/04/04. doi:
10.3201/eid2607.200839. PubMed PMID: 32243255.

32.   Danis K, Epaulard O, Benet T, Gaymard A, Campoy S, Bothelo-Nevers E, Bouscambert-
Duchamp M, Spaccaferri G, Ader F, Mailles A, Boudalaa Z, Tolsma V, Berra J, Vaux S, Forestier E,
Landelle C, Fougere E, Thabuis A, Berthelot P, Veil R, Levy-Bruhl D, Chidiac C, Lina B, Coignard B,
Saura C, Investigation Team. Cluster of Coronavirus Disease 2019 (Covid-19) in the French Alps,
2020. Clin Infect Dis. 2020. Epub 2020/04/12. doi: 10.1093/cid/ciaa424. PubMed PMID: 32277759;
PubMed Central PMCID: 7184384.

33.   He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y,
Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM.
Temporal Dynamics in Viral Shedding and Transmissibility of Covid-19. Nat Med. 2020. Epub
2020/04/17. doi: 10.1038/s41591-020-0869-5. PubMed PMID: 32296168.

34.   Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, Behrens P, Boddinghaus
B, Gotsch U, Naujoks F, Neumann P, Schork J, Tiarks-Jungk P, Walczok A, Eickmann M, Vehreschild
M, Kann G, Wolf T, Gottschalk R, Ciesek S. Evidence of Sars-Cov-2 Infection in Returning Travelers
from Wuhan, China. N Engl J Med. 2020;382(13):1278-80. Epub 2020/02/19. doi:
10.1056/NEJMc2001899. PubMed PMID: 32069388; PubMed Central PMCID: 7121749.

35.   Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar
S, Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark S,
Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA, Honein MA,
Reddy SC, Jernigan JA, Public Health S, King C, Team CC-I. Asymptomatic and Presymptomatic Sars-
Cov-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington,
March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-81. Epub 2020/04/03. doi:
10.15585/mmwr.mm6913e1. PubMed PMID: 32240128; PubMed Central PMCID: PMC7119514

36.   Luo L, Liu D, Liao X-l, Wu X-b, Jing Q-l, Zheng J-z, Liu F-h, Yang S-g, Bi B, Li Z-h, Liu J-p, Song
W-q, Zhu W, Wang Z-h, Zhang X-r, Chen P-l, Liu H-m, Cheng X, Cai M-c, Huang Q-m, Yang P, Yang X-f,
Huang Z-g, Tang J-l, Ma Y, Mao C. Modes of Contact and Risk of Transmission in Covid-19 among
Close Contacts. bioRxiv. [Preprint]. 2020. doi: 10.1101/2020.03.24.20042606. PubMed PMID.

37.   Lytras T, Dellis G, Flountzi A, Hatzianastasiou S, Nikolopoulou G, Tsekou K, Diamantis Z,
Stathopoulou G, Togka M, Gerolymatos G, Rigakos G, Sapounas S, Tsiodras S. High Prevalence of
Sars-Cov-2 Infection in Repatriation Flights to Greece from Three European Countries. J Travel Med.
2020. Epub 2020/04/17. doi: 10.1093/jtm/taaa054. PubMed PMID: 32297940; PubMed Central
PMCID: 7184451.

38.   Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, Lu Z, Shen X, Fan T, Jiang W, Yang W, Li T,
Chen J, Geng Q. Ct Imaging and Clinical Course of Asymptomatic Cases with Covid-19 Pneumonia at
Admission in Wuhan, China. J Infect. 2020. Epub 2020/04/16. doi: 10.1016/j.jinf.2020.04.004.
PubMed PMID: 32294504; PubMed Central PMCID: 7152865.

39.   Pongpirul WA, Mott JA, Woodring JV, Uyeki TM, MacArthur JR, Vachiraphan A,
Suwanvattana P, Uttayamakul S, Chunsuttiwat S, Chotpitayasunondh T, Pongpirul K, Prasithsirikul W.
Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand. Emerg Infect Dis.
2020;26(7). Epub 2020/04/09. doi: 10.3201/eid2607.200598. PubMed PMID: 32267826.

40.   Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and Epidemiological Features of 36
Children with Coronavirus Disease 2019 (Covid-19) in Zhejiang, China: An Observational Cohort
Study. Lancet Infect Dis. 2020. Epub 2020/03/30. doi: 10.1016/S1473-3099(20)30198-5. PubMed
PMID: 32220650; PubMed Central PMCID: PMC7158906.

41.   See KC, Liew SM, Ng DCE, Chew EL, Khoo EM, Sam CH, Sheena D, Zahilah Filzah Z, Chin SY,
Lee PY, Tan LP, Farah Najwa Z, Sabrina S, Them WW, Saipriya T, Muhammad Zamakhshari ZA, Cheah
WK, Peariasamy K, Goh PP, Ibrahim H. Covid-19: Four Paediatric Cases in Malaysia. Int J Infect Dis.
2020;94:125-7. Epub 2020/04/19. doi: 10.1016/j.ijid.2020.03.049. PubMed PMID: 32304822;
PubMed Central PMCID: PMC7158792.

42.   Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and Clinical Characteristics of 10
Children with Coronavirus Disease 2019 in Changsha, China. J Clin Virol. 2020;127(NA):104353. Epub
2020/04/18. doi: 10.1016/j.jcv.2020.104353. PubMed PMID: 32302953; PubMed Central PMCID:
PMC7195108.

43.   Tian S, Wu M, Chang Z, Wang Y, Zhou G, Zhang W, Xing J, Tian H, Zhang X, Zou X, Zhang L, Liu
M, Chen J, Han J, Ning K, Chen S, Wu T. Epidemiological Investigation and Intergenerational Clinical
Characteristics of 24 Covid-19 Patients Associated with Supermarket Cluster. bioRxiv. [Preprint].
2020. doi: 10.1101/2020.04.11.20058891. PubMed PMID.

44.   Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, Zhang YL, Yan JB. Potential Presymptomatic
Transmission of Sars-Cov-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5):1052-4.

Epub 2020/02/25. doi: 10.3201/eid2605.200198. PubMed PMID: 32091386; PubMed Central PMCID:
PMC7181913.

45.   Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, Ge L, Wang F, Chen Q, Zhang Y, Zhao Q.
Clinical Characteristics of Non-Critically Ill Patients with Novel Coronavirus Infection (Covid-19) in a
Fangcang Hospital. Clin Microbiol Infect. 2020. Epub 2020/04/07. doi: 10.1016/j.cmi.2020.03.032.
PubMed PMID: 32251842; PubMed Central PMCID: PMC7195539.

46.   Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical Outcome of 55 Asymptomatic Cases at
the Time of Hospital Admission Infected with Sars-Coronavirus-2 in Shenzhen, China. J Infect Dis.
2020. Epub 2020/03/18. doi: 10.1093/infdis/jiaa119. PubMed PMID: 32179910; PubMed Central
PMCID: PMC7184401.

47.   Wang Z, Ma W, Zheng X, Wu G, Zhang R. Household Transmission of Sars-Cov-2. J Infect.
2020;NA(NA). Epub 2020/04/14. doi: 10.1016/j.jinf.2020.03.040. PubMed PMID: 32283139; PubMed
Central PMCID: PMC7151261.

48.   Yang N, Shen Y, Shi C, Ma AHY, Zhang X, Jian X, Wang L, Shi J, Wu C, Li G, Fu Y, Wang K, Lu M,
Qian G. In-Flight Transmission Cluster of Covid-19: A Retrospective Case Series. bioRxiv. [Preprint].
2020. doi: 10.1101/2020.03.28.20040097. PubMed PMID.

49.   Ye F, Xu S, Rong Z, Xu R, Liu X, Deng P, Liu H, Xu X. Delivery of Infection from Asymptomatic
Carriers of Covid-19 in a Familial Cluster. Int J Infect Dis. 2020;94:133-8. Epub 2020/04/06. doi:
10.1016/j.ijid.2020.03.042. PubMed PMID: 32247826; PubMed Central PMCID: PMC7129961.

50.   Zhang J, Tian S, Lou J, Chen Y. Familial Cluster of Covid-19 Infection from an Asymptomatic.
Crit Care. 2020;NA(NA). doi: 10.1186/s13054-020-2817-7. PubMed PMID.

51.   Zhang W. Estimating the Presymptomatic Transmission of Covid19 Using Incubation Period
and Serial Interval Data. bioRxiv. [Preprint]. 2020. doi: 10.1101/2020.04.02.20051318. PubMed
PMID.

52.   Zhou X, Li Y, Li T, Zhang W. Follow-up of Asymptomatic Patients with Sars-Cov-2 Infection.
Clin Microbiol Infect. 2020. Epub 2020/04/03. doi: 10.1016/j.cmi.2020.03.024. PubMed PMID:
32234453.

53.   Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T,
He J, Yen HL, Peiris M, Wu J. Sars-Cov-2 Viral Load in Upper Respiratory Specimens of Infected
Patients. N Engl J Med. 2020;382(12):1177-9. Epub 2020/02/20. doi: 10.1056/NEJMc2001737.
PubMed PMID: 32074444; PubMed Central PMCID: PMC7121626.

54.   Alshami AA, Alattas RA, Anan HF, Al Qahtani HS, Al Mulhim MA, Alahilmi AA, Alfaraj AH.
Silent Disease and Loss of Taste and Smell Are Common Manifestations of Sars-Cov-2 Infection in a
Quarantine Facility: First Report from Saudi Arabia. MedRxiv. [Preprint]. 2020. doi:
10.1101/2020.05.13.20100222. PubMed PMID.

55.   Al-Shamsi HO, Coomes EA, Alrawi S. Screening for Covid-19 in Asymptomatic Patients with
Cancer in a Hospital in the United Arab Emirates. JAMA Oncol. 2020. doi:
10.1001/jamaoncol.2020.2548. PubMed PMID.

56.   Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, Baptiste CD, Breslin N, D'Alton ME,
Fuchs KM, Goffman D, Gyamfi-Bannerman C, Matseoane-Peterssen DN, Miller RS, Sheen JJ, Simpson
LL, Sutton D, Zork N, Friedman AM. Symptoms and Critical Illness among Obstetric Patients with

Coronavirus Disease 2019 (Covid-19) Infection. Obstet Gynecol. 2020. doi: 10.1097/AOG.0000000000003996. PubMed PMID.

57.   Angelo Vaira L, Hopkins C, Salzano G, Petrocelli M, Melis A, Cucurullo M, Ferrari M, Gagliardini L, Pipolo C, Deiana G, Fiore V, De Vito A, Turra N, Canu S, Antonio Maglio A, Serra A, Bussu F, Madeddu G, Babudieri S, Giuseppe Fois A, Pirina P, Salzano FA, De Riu P, Biglioli F, De Riu G. Olfactory and Gustatory Function Impairment in Covid-19 Patients: Italian Objective Multicenter-Study. Head Neck. 2020. doi: 10.1002/hed.26269. PubMed PMID.

58.   Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA. Presymptomatic Sars-Cov-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020. doi: 10.1056/NEJMoa2008457. PubMed PMID.

59.   Bai K, Liu W, Liu C, Fu Y, Hu J, Qin Y, Zhang Q, Chen H, Xu F, Li C. Clinical Analysis of 25 Novel Coronavirus Infections in Children. Pediatr Infect Dis J. 2020. doi: 10.1097/INF.0000000000002740. PubMed PMID.

60.   Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, Liu X, Wei L, Truelove SA, Zhang T, Gao W, Cheng C, Tang X, Wu X, Wu Y, Sun B, Huang S, Sun Y, Zhang J, Ma T, Lessler J, Feng T. Epidemiology and Transmission of Covid-19 in 391 Cases and 1286 of Their Close Contacts in Shenzhen, China: A Retrospective Cohort Study. Lancet Infect Dis. 2020. Epub 2020/05/01. doi: 10.1016/S1473-3099(20)30287-5. PubMed PMID: 32353347; PubMed Central PMCID: PMC7185944.

61.   Bohmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, Bohm S, Woudenberg T, Ackermann N, Konrad R, Eberle U, Treis B, Dangel A, Bengs K, Fingerle V, Berger A, Hormansdorfer S, Ippisch S, Wicklein B, Grahl A, Portner K, Muller N, Zeitlmann N, Boender TS, Cai W, Reich A, An der Heiden M, Rexroth U, Hamouda O, Schneider J, Veith T, Muhlemann B, Wolfel R, Antwerpen M, Walter M, Protzer U, Liebl B, Haas W, Sing A, Drosten C, Zapf A. Investigation of a Covid-19 Outbreak in Germany Resulting from a Single Travel-Associated Primary Case: A Case Series. Lancet Infect Dis. 2020. Epub 2020/05/19. doi: 10.1016/S1473-3099(20)30314-5. PubMed PMID: 32422201; PubMed Central PMCID: PMC7228725.

62.   Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva A, Borchers N, Gruber R, Ambrosch A, Kabesch M. Symptoms and Immunoglobulin Development in Hospital Staff Exposed to a Sars-Cov-2 Outbreak. Pediatr Allergy Immunol. 2020. doi: 10.1111/pai.13278. PubMed PMID.

63.   Casey M, Griffin J, McAloon CG, Byrne AW, Madden JM, McEvoy D, Collins AB, Hunt K, Barber A, Butler F, Lane EA, O Brien K, Wall P, Walsh KA, More SJ. Estimating Pre-Symptomatic Transmission of Covid-19: A Secondary Analysis Using Published Data. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.08.20094870. PubMed PMID.

64.   Chang MC, Hur J, Park D. Chest Computed Tomography Findings in Asymptomatic Patients with Covid-19. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.09.20096370. PubMed PMID.

65.   Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Sars-Cov-2 Transmission in Different Settings: Analysis of Cases and Close Contacts from the Tablighi Cluster in Brunei Darussalam. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.04.20090043. PubMed PMID.

66.   Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, Taiwan C-OIT. Contact Tracing Assessment of Covid-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods

before and after Symptom Onset. JAMA Intern Med. 2020. Epub 2020/05/02. doi:
10.1001/jamainternmed.2020.2020. PubMed PMID: 32356867; PubMed Central PMCID:
PMC7195694.

67.   Choe PG, Kang EK, Lee SY, Oh B, Im D, Lee HY, Jung H, Kang CK, Kim MS, Park WB, Choi EH,
Cho B, Oh MD, Kim NJ. Selecting Coronavirus Disease 2019 Patients with Negligible Risk of
Progression: Early Experience from Non-Hospital Isolation Facility in Korea. Korean J Intern Med.
2020. doi: 10.3904/kjim.2020.159. PubMed PMID.

68.   Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, Kern HS, Graber CJ, Goetz MB.
Universal and Serial Laboratory Testing for Sars-Cov-2 at a Long-Term Care Skilled Nursing Facility for
Veterans - Los Angeles, California, 2020. MMWR Morb Mortal Wkly Rep. 2020. doi:
10.15585/mmwr.mm6921e1. PubMed PMID.

69.   Emery JC, Russel TW, Liu Y, Hellewell J, Pearson CA, group Cnw, Knight GM, Eggo RM,
Kucharski AJ, Funk S, Flasche S, Houben RMGJ. The Contribution of Asymptomatic Sars-Cov-2
Infections to Transmission - a Model-Based Analysis of the Diamond Princess Outbreak. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.05.07.20093849. PubMed PMID.

70.   Gao Y, Shi C, Chen Y, Shi P, Liu J, Xiao Y, Shen Y, Chen E. A Cluster of the Corona Virus Disease
2019 Caused by Incubation Period Transmission in Wuxi, China. J Infect. 2020. doi:
10.1016/j.jinf.2020.03.042. PubMed PMID.

71.   Graham N, Junghans C, Downes R, Sendall C, Lai H, McKirdy A, Elliott P, Howard R, Wingfield
D, Priestman M, Ciechonska M, Cameron L, Storch M, Crone MA, Freemont PS, Randell P, McLaren R,
Lang N, Ladhani S, Sanderson F, Sharp DJ. Sars-Cov-2 Infection, Clinical Features and Outcome of
Covid-19 in United Kingdom Nursing Homes. J Infect. 2020. doi: 10.1016/j.jinf.2020.05.073. PubMed
PMID.

72.   Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Giménez-Arnau AM, Joly P, Vestergaard
C, Sticherling M, Schmidt E. Sars-Cov-2 Transmission from Presymptomatic Meeting Attendee,
Germany. Emerg Infect Dis. 2020. doi: 10.3201/eid2608.201235. PubMed PMID.

73.   Huang L, Jiang J, Li X, Zhou Y, Xu M, Zhou J. Initial Ct Imaging Characters of an Imported
Family Cluster of Covid-19. Clin Imaging. 2020. doi: 10.1016/j.clinimag.2020.04.010. PubMed PMID.

74.   Huang R, Zhao H, Wang J, Yan X, Shao H, Wu C. A Family Cluster of Covid-19 Involving an
Asymptomatic Case with Persistently Positive Sars-Cov-2 in Anal Swabs. Travel Med Infect Dis. 2020.
doi: 10.1016/j.tmaid.2020.101745. PubMed PMID.

75.   Jiang X, Luo M, Zou Z, Wang X, Chen C, Qiu J. Asymptomatic Sars-Cov-2 Infected Case with
Viral Detection Positive in Stool but Negative in Nasopharyngeal Samples Lasts for 42 Days. J Med
Virol. 2020. doi: 10.1002/jmv.25941. PubMed PMID.

76.   Jiang XL, Zhang XL, Zhao XN, Li CB, Lei J, Kou ZQ, Sun WK, Hang Y, Gao F, Ji SX, Lin CF, Pang B,
Yao MX, Anderson BD, Wang GL, Yao L, Duan LJ, Kang DM, Ma MJ. Transmission Potential of
Asymptomatic and Paucisymptomatic Sars-Cov-2 Infections: A Three-Family Cluster Study in China. J
Infect Dis. 2020. doi: 10.1093/infdis/jiaa206. PubMed PMID.

77.   Kim SE, Jeong HS, Yu Y, Shin SU, Kim S, Oh TH, Kim UJ, Kang SJ, Jang HC, Jung SI, Park KH.
Viral Kinetics of Sars-Cov-2 in Asymptomatic Carriers and Presymptomatic Patients. Int J Infect Dis.
2020. doi: 10.1016/j.ijid.2020.04.083. PubMed PMID.

78.   Kim Y, Chun JY, Baek G. Transmission Onset Distribution of Covid-19 in South Korea.
medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.13.20101246. PubMed PMID.

79.   Kong W, Wang Y, Hu J, Chughtai A, Pu H. Comparison of Clinical and Epidemiological
Characteristics of Asymptomatic and Symptomatic Sars-Cov-2 Infection: A Multi-Center Study in
Sichuan Province, China. Travel Med Infect Dis. 2020. doi: 10.1016/j.tmaid.2020.101754. PubMed
PMID.

80.   Kumar R, Bhattacharya B, Meena VP, Aggarwal A, Tripathi M, Soneja M, Mittal A, Singh K,
Gupta N, Garg RK, Ratre B, Kumar B, Bhopale S, Tiwari P, Verma A, Bhatnagar S, Mohan A, Wig N,
Guleria R. Management of Mild Covid-19: Policy Implications of Initial Experience in India. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.05.20.20107664. PubMed PMID.

81.   Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, Rossi L,
Manganelli R, Loregian A, Navarin N, Abate D, Sciro M, Merigliano S, De Canale E, Vanuzzo MC,
Besutti V, Saluzzo F, Onelia F, Pacenti M, Parisi S, Carretta G, Donato D, Flor L, Cocchio S, Masi G,
Sperduti A, Cattarino L, Salvador R, Nicoletti M, Caldart F, Castelli G, Nieddu E, Labella B, Fava L,
Drigo M, Gaythorpe KAM, Imperial College C-RT, Brazzale AR, Toppo S, Trevisan M, Baldo V, Donnelly
CA, Ferguson NM, Dorigatti I, Crisanti A. Suppression of a Sars-Cov-2 Outbreak in the Italian
Municipality of Vo'. Nature. 2020. Epub 2020/07/01. doi: 10.1038/s41586-020-2488-1. PubMed
PMID: 32604404.

82.   Lombardi A, Consonni D, Carugno M, Bozzi G, Mangioni D, Muscatello A, Castelli V, Palomba
E, Cantu AP, Ceriotti F, Tiso B, Pesatori AC, Riboldi L, Bandera A, Gori A. Characteristics of 1,573
Healthcare Workers Who Underwent Nasopharyngeal Swab for Sars-Cov-2 in Milano, Lombardy,
Italy. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.07.20094276. PubMed PMID.

83.   London V, McLaren R, Atallah F, Cepeda C, McCalla S, Fisher N, Stein JL, Haberman S, Minkoff
H. The Relationship between Status at Presentation and Outcomes among Pregnant Women with
Covid-19. Am J Perinatol. 2020. doi: 10.1055/s-0040-1712164. PubMed PMID.

84.   Lu Y, Li Y, Deng W, Liu M, He Y, Huang L, Lv M, Li J, Du H. Symptomatic Infection Is Associated
with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study
of 110 Children in Wuhan. Pediatr Infect Dis J. 2020. doi: 10.1097/INF.0000000000002729. PubMed
PMID.

85.   Luo Y, Trevathan E, Qian Z, Li Y, Li J, Xiao W, Tu N, Zeng Z, Mo P, Xiong Y, Ye G. Asymptomatic
Sars-Cov-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. Emerg Infect
Dis. 2020. doi: 10.3201/eid2608.201016. PubMed PMID.

86.   Ma Y, Xu QN, Wang FL, Ma XM, Wang XY, Zhang XG, Zhang ZF. Characteristics of
Asymptomatic Patients with Sars-Cov-2 Infection in Jinan, China. Microbes Infect. 2020. doi:
10.1016/j.micinf.2020.04.011. PubMed PMID.

87.   Melgosa M, Madrid A, Alvárez O, Lumbreras J, Nieto F, Parada E, Perez-Beltrán V. Sars-Cov-2
Infection in Spanish Children with Chronic Kidney Pathologies. Pediatr Nephrol. 2020. doi:
10.1007/s00467-020-04597-1. PubMed PMID.

88.   Merza MA, Haleem Al Mezori AA, Mohammed HM, Abdulah DM. Covid-19 Outbreak in Iraqi
Kurdistan: The First Report Characterizing Epidemiological, Clinical, Laboratory, and Radiological
Findings of the Disease. Diabetes Metab Syndr Clin Res Rev. 2020. doi: 10.1016/j.dsx.2020.04.047.
PubMed PMID.

89. Noh JY, Yoon JG, Seong H, Choi WS, Sohn JW, Cheong HJ, Kim WJ, Song JY. Asymptomatic
Infection and Atypical Manifestations of Covid-19: Comparison of Viral Shedding Duration. J Infect.
2020. doi: 10.1016/j.jinf.2020.05.035. PubMed PMID.

90. Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, Kim JI, Kim HS, Kim YB, Park Y, Huh IS, Kim HK,
Yoon HJ, Jang H, Kim K, Chang Y, Kim I, Lee H, Gwack J, Kim SS, Kim M, Kweon S, Choe YJ, Park O,
Park YJ, Jeong EK. Coronavirus Disease Outbreak in Call Center, South Korea. Emerg Infect Dis. 2020.
doi: 10.3201/eid2608.201274. PubMed PMID.

91. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, Buckee CO. Individual Quarantine
Versus Active Monitoring of Contacts for the Mitigation of Covid-19: A Modelling Study. Lancet
Infect Dis. 2020. doi: 10.1016/S1473-3099(20)30361-3. PubMed PMID.

92. Qiu C, Deng Z, Xiao Q, Shu Y, Deng Y, Wang H, Liao X, Liu H, Zhou D, Zhao X, Zhou J, Wang J,
Shi Z, Long D. Transmission and Clinical Characteristics of Coronavirus Disease 2019 in 104 Outside-
Wuhan Patients, China. J Med Virol. 2020. doi: 10.1002/jmv.25975. PubMed PMID.

93. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, Young J, Pereira-Dias J,
Hamilton WL, Ferris M, Torok ME, Meredith L, Collaboration C-NC-B, Curran MD, Fuller S, Chaudhry
A, Shaw A, Samworth RJ, Bradley JR, Dougan G, Smith KGC, Lehner PJ, Matheson NJ, Wright G,
Goodfellow IG, Baker S, Weekes MP. Screening of Healthcare Workers for Sars-Cov-2 Highlights the
Role of Asymptomatic Carriage in Covid-19 Transmission. Elife. 2020;9. Epub 2020/05/12. doi:
10.7554/eLife.58728. PubMed PMID: 32392129.

94. Roxby AC, Greninger AL, Hatfield KM, Lynch JB, Dellit TH, James A, Taylor J, Page LC, Kimball
A, Arons M, Munanga A, Stone N, Jernigan JA, Reddy SC, Lewis J, Cohen SA, Jerome KR, Duchin JS,
Neme S. Outbreak Investigation of Covid-19 among Residents and Staff of an Independent and
Assisted Living Community for Older Adults in Seattle, Washington. JAMA Intern Med. 2020. doi:
10.1001/jamainternmed.2020.2233. PubMed PMID.

95. Schwierzeck V, König JC, Kühn J, Mellmann A, Correa-Martínez CL, Omran H, Konrad M,
Kaiser T, Kampmeier S. First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome
Coronavirus 2 (Sars-Cov-2) in a Pediatric Dialysis Unit. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa491.
PubMed PMID.

96. Sharma AK, Ahmed A, Baig VN, Dhakad P, Dalela G, Kacker S, Panwar VR, Panwar RB, Gupta
R. Characteristics and Outcomes of Hospitalized Young Adults with Mild to Moderate Covid-19 at a
University Hospital in India. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.06.02.20106310. PubMed
PMID.

97. Solbach W, Schiffner J, Backhaus I, Burger D, Staiger R, Tiemer B, Bobrowski A, Hutchings T,
Mischnik A. Antibody Profiling of Covid-19 Patients in an Urban Low-Incidence Region in Northern
Germany. medRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.30.20111393. PubMed PMID.

98. Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical Features of Pediatric Patients with
Coronavirus Disease (Covid-19). J Clin Virol. 2020. doi: 10.1016/j.jcv.2020.104377. PubMed PMID.

99. Tan X, Huang J, Zhao F, Zhou Y, Li JQ, Wang XY. [Clinical Features of Children with Sars-Cov-2
Infection: An Analysis of 13 Cases from Changsha, China]. Zhongguo Dang Dai Er Ke Za Zhi. 2020. doi:
10.7499/j.issn.1008-8830.2003199. PubMed PMID.

100. Pham TQ, Rabaa MA, Duong LH, Dang TQ, Tran QD, Quach HL, Hoang NA, Phung DC, Ngu ND,
Tran AT, La NQ, Tran MP, Vinh C, Nguyen KC, Anh DD, T.N. D, Thwaites GE, van Doorn HR, Choisy M,

OUCRU Covid-19 Research Group. The First 100 Days of Sars-Cov-2 Control in Vietnam. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.05.12.20099242. PubMed PMID.

101.   Treibel TA, Manisty C, Burton M, McKnight NA, Lambourne J, Augusto JB, Couto-Parada X,
Cutino-Moguel T, Noursadeghi M, Moon JC. Covid-19: Pcr Screening of Asymptomatic Health-Care
Workers at London Hospital. Lancet. 2020. doi: 10.1016/S0140-6736(20)31100-4. PubMed PMID.

102.   Wang Y, Tong J, Qin Y, Xie T, Li J, Li J, Xiang J, Cui Y, Higgs ES, Xiang J, He Y. Characterization
of an Asymptomatic Cohort of Sars-Cov-2 Infected Individuals Outside of Wuhan, China. Clin Infect
Dis. 2020. doi: 10.1093/cid/ciaa629. PubMed PMID.

103.   Wong J, Abdul Aziz ABZ, Chaw L, Mahamud A, Griffith MM, Ying-Ru LO, Naing L. High
Proportion of Asymptomatic and Presymptomatic Covid-19 Infections in Travelers and Returning
Residents to Brunei. J Travel Med. 2020. doi: 10.1093/jtm/taaa066. PubMed PMID.

104.   Wu HP, Li BF, Chen X, Hu HZ, Jiang SA, Cheng H, Hu XH, Tang JX, Zhong FC, Zeng LW, Yu W,
Yuan Y, Wu XF, Li YP, Zheng ZL, Pan TB, Wu ZX, Yuan JF, Chen Q. Clinical Features of Coronavirus
Disease 2019 in Children Aged <18 Years in Jiangxi, China: An Analysis of 23 Cases. Zhongguo Dang
Dai Er Ke Za Zhi. 2020. doi. PubMed PMID.

105.   Wu J, Huang Y, Tu C, Bi C, Chen Z, Luo L, Huang M, Chen M, Tan C, Wang Z, Wang K, Liang Y,
Huang J, Zheng X, Liu J. Household Transmission of Sars-Cov-2, Zhuhai, China, 2020. Clin Infect Dis.
2020. doi: 10.1093/cid/ciaa557. PubMed PMID.

106.   Xu H, Liu E, Xie J, Smyth R, Zhou Q, Zhao R, Zang N, Long X, Tang Y, Estill J, Yang S, Zhu J, Yan
X, Gong F, Tian W, Zhou X, Mo Y, Xiao H, Tang Z, Chen Y, Wang Y, Cui Y, Fang X, Li F, Tian Y, Li P, Deng
Q, Ren C, He R, Li Y, Qin H, Wang A, Deng H, Wu J, Meng W, Li W, Zhao Y, Luo Z, Wang Z, Cheng Y,
Wang G, Li Q. A Follow-up Study of Children Infected with Sars-Cov-2 from Western China. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.04.20.20073288. PubMed PMID.

107.   Xu T, Huang R, Zhu L, Wang J, Cheng J, Zhang B, Zhao H, Chen K, Shao H, Zhu C, Wu C, Liu L.
Epidemiological and Clinical Features of Asymptomatic Patients with Sars-Cov-2 Infection. J Med
Virol. 2020. doi: 10.1002/jmv.25944. PubMed PMID.

108.   Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic
Vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. JAMA Netw Open. 2020. doi:
10.1001/jamanetworkopen.2020.10182. PubMed PMID.

109.   Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. Different Longitudinal Patterns
of Nucleic Acid and Serology Testing Results Based on Disease Severity of Covid-19 Patients. Emerg
Microbes Infect. 2020. doi: 10.1080/22221751.2020.1756699. PubMed PMID.

110.   Zhang B, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, Zhang S. Positive Rectal Swabs in Young
Patients Recovered from Coronavirus Disease 2019 (Covid-19). J Infect. 2020. doi:
10.1016/j.jinf.2020.04.023. PubMed PMID.

111.   Zhang W, Cheng W, Luo L, Ma Y, Xu C, Qin P, Zhang Z. Secondary Transmission of
Coronavirus Disease from Presymptomatic Persons, China. Emerg Infect Dis. 2020. doi:
10.3201/eid2608.201142. PubMed PMID.

112.   Zhang W, Long Q, Huang Y, Chen C, Wu J, Hong Y, Zhou H, Wu W. Asymptomatic Covid-19
Have Longer Treatment Cycle Than Moderate Type of Confirmed Patients. medRxiv. [Preprint]. 2020.
doi: 10.1101/2020.05.16.20103796. PubMed PMID.

113. Zhang Z, Xiao T, Wang Y, Yuan J, Ye H, Wei L, Wang H, Liao X, Qian S, Wang Z, Liu L. Early
Viral Clearance and Antibody Kinetics of Covid-19 among Asymptomatic Carriers. medRxiv.
[Preprint]. 2020. doi: 10.1101/2020.04.28.20083139. PubMed PMID.

114. Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, Wu X. Viral Dynamics in Asymptomatic Patients
with Covid-19. Int J Infect Dis. 2020. doi: 10.1016/j.ijid.2020.05.030. PubMed PMID.

115. Savvides C, Siegel R. Asymptomatic and Presymptomatic Transmission of Sars-Cov-2: A
Systematic Review. medRxiv [Preprint]. 2020:2020.06.11.20129072. doi:
10.1101/2020.06.11.20129072. PubMed PMID: 32587980.

116. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, Ngoc NM, Dung NT,
Man DNH, Nguyet LA, Nhat LTH, Nhu LNT, Ny NTH, Hong NTT, Kestelyn E, Dung NTP, Xuan TC, Hien
TT, Thanh Phong N, Tu TNH, Geskus RB, Thanh TT, Thanh Truong N, Binh NT, Thuong TC, Thwaites G,
Tan LV. The Natural History and Transmission Potential of Asymptomatic Sars-Cov-2 Infection. Clin
Infect Dis. 2020. doi: ciaa711. PubMed PMID.

117. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of
Reverse Transcriptase Polymerase Chain Reaction-Based Sars-Cov-2 Tests by Time since Exposure.
Ann Intern Med. 2020. Epub 2020/05/19. doi: 10.7326/M20-1495. PubMed PMID: 32422057;
PubMed Central PMCID: PMC7240870.

118. Heneghan C, Brassey J, Jefferson T. **Covid-19: What Proportion Are Asymptomatic?** Oxford:
Centre for Evidence Based Medicine; 2020 [Access Date:updated 06.04.202023.04.2020]. Available
from: https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/.

119. He J, Guo Y, Mao R, Zhang J. Proportion of Asymptomatic Coronavirus Disease 2019 (Covid-
19): A Systematic Review and Meta-Analysis. J Med Virol. 2020. Epub 2020/07/22. doi:
10.1002/jmv.26326. PubMed PMID: 32691881.

120. Beale S, Hayward A, Shallcross L, Aldridge RW, Fragaszy E. A Rapid Review of the
Asymptomatic Proportion of Pcr-Confirmed Sars-Cov-2 Infections in Community Settings. medRxiv.
[Preprint]. 2020:2020.05.20.20108183. doi: 10.1101/2020.05.20.20108183. PubMed PMID.

121. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the Extent of
True Asymptomatic Covid-19 and Its Potential for Community Transmission: Systematic Review and
Meta-Analysis. MedRxiv. [Preprint]. 2020. doi: 10.1101/2020.05.10.20097543. PubMed PMID.

122. Day M. Covid-19: Four Fifths of Cases Are Asymptomatic, China Figures Indicate. BMJ.
2020;369:m1375. Epub 2020/04/04. doi: 10.1136/bmj.m1375. PubMed PMID: 32241884.

123. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S,
Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM,
Van den Bruel A, Cochrane C-DTAG. Antibody Tests for Identification of Current and Past Infection
with Sars-Cov-2. Cochrane Database Syst Rev. 2020;6:CD013652. Epub 2020/06/26. doi:
10.1002/14651858.CD013652. PubMed PMID: 32584464.

124. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of Sars-Cov-2
- Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):411-5. Epub
2020/04/10. doi: 10.15585/mmwr.mm6914e1. PubMed PMID: 32271722; PubMed Central PMCID:
PMC7147908

125. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F,
Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and Immunological Assessment of
Asymptomatic Sars-Cov-2 Infections. Nat Med. 2020. Epub 2020/06/20. doi: 10.1038/s41591-020-
0965-6. PubMed PMID: 32555424.

126. Ludvigsson JF. Systematic Review of Covid-19 in Children Shows Milder Cases and a Better
Prognosis Than Adults. Acta Paediatr. 2020;109(6):1088-95. Epub 2020/03/24. doi:
10.1111/apa.15270. PubMed PMID: 32202343; PubMed Central PMCID: PMC7228328.

127. von Wyl V, Bonhoeffer S, Bugnion E, Puhan MA, Salathe M, Stadler T, Troncoso C, Vayena E,
Low N. A Research Agenda for Digital Proximity Tracing Apps. Swiss Med Wkly. 2020;150:w20324.
Epub 2020/07/17. doi: 10.4414/smw.2020.20324. PubMed PMID: 32672340.